Shorts On Watch: After Reaching Milestone, Is Dynavax Tech Corporation (NASDAQ:DVAX)’s Short Interest Revealing Something?

December 1, 2016 - By Nellie Frank   ·   0 Comments

Shorts On Watch: After Reaching Milestone, Is Dynavax Tech Corporation (NASDAQ:DVAX)’s Short Interest Revealing Something?

The stock of Dynavax Tech Corporation (NASDAQ:DVAX) registered an increase of 10.35% in short interest. DVAX’s total short interest was 11.52 million shares in December as published by FINRA. Its up 10.35% from 10.44M shares, reported previously. With 810,800 shares average volume, it will take short sellers 14 days to cover their DVAX’s short positions. The short interest to Dynavax Tech Corporation’s float is 34%. The stock last traded at $4.3 per share. It is down 75.47% since April 28, 2016 and is downtrending. It has underperformed by 81.40% the S&P500.

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company. The company has a market cap of $149.97 million. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. It currently has negative earnings. The Company’s development programs are focused on vaccines and cancer immunotherapy.

Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.26, from 1.02 in 2016Q1. The ratio is positive, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Alpine Prtn Vi last reported 13,000 shares in the company. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Morgan Stanley holds 290,285 shares or 0% of its portfolio. The Ontario – Canada-based Royal Savings Bank Of Canada has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Moreover, Schwab Charles Invest Mgmt Incorporated has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 131,952 shares. Ameriprise Fincl has invested 0.01% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Boston Advisors Ltd Liability Corp, a Massachusetts-based fund reported 12,330 shares. Blackrock Fund Advisors has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Howard Hughes Med Institute reported 21,355 shares or 0.1% of all its holdings. Northern Tru last reported 468,166 shares in the company. Putnam Invests Ltd Liability Corp has 0.01% invested in the company for 175,729 shares. Panagora Asset Mngmt Incorporated accumulated 0.02% or 340,600 shares. Manufacturers Life The, a Ontario – Canada-based fund reported 27,406 shares. Mutual Of America Capital Lc holds 0.01% or 21,900 shares in its portfolio. Falcon Point Capital Limited Liability Company accumulated 0.05% or 21,753 shares.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Zacks given on Wednesday, August 12. On Wednesday, April 27 the stock rating was downgraded by JP Morgan to “Neutral”. RBC Capital Markets initiated the shares of DVAX in a report on Monday, November 30 with “Outperform” rating. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Thursday, April 28 report.

DVAX Company Profile

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

More important recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Seekingalpha.com which released: “SD-101: The Other Side Of Dynavax” on November 30, 2016, also Prnewswire.com published article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …”, Investorplace.com published: “Why Dynavax Technologies Corporation (DVAX), Petroleo Brasileiro SA Petrobras …” on November 14, 2016. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) was released by: 247Wallst.com and their article: “Why Dynavax Shares Are in Freefall” with publication date: November 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>